005500 — Samjin Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩239bn
- KR₩365bn
- KR₩308bn
- 72
- 82
- 62
- 87
Annual balance sheet for Samjin Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 24,489 | 11,711 | 4,663 | 4,006 | 3,705 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 51,429 | 57,684 | 59,883 | 61,455 | 62,673 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 146,860 | 139,872 | 134,268 | 146,180 | 159,105 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 102,526 | 168,901 | 198,068 | 191,640 | 192,505 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 269,033 | 332,496 | 406,557 | 419,901 | 425,166 | 
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 33,935 | 49,514 | 81,652 | 144,550 | 159,130 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 55,577 | 98,328 | 131,213 | 154,536 | 163,511 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 213,456 | 234,168 | 275,344 | 265,365 | 261,655 | 
| Total Liabilities & Shareholders' Equity | 269,033 | 332,496 | 406,557 | 419,901 | 425,166 | 
| Total Common Shares Outstanding |